On April 22, Crus Shuanghe held the Fei Tong ® National Listing Conference in the form of "Cloud Live Broadcast". Crus Shuanghe said that the product listing marks another heavy product in the pediatric field of CR Shuanghe, the pediatric product line is further enriched, and the development of the pediatric field will be more in-depth.
According to reports, caffeine citrate injection is used to treat primary apnea in premature newborns, and is a national medical insurance class B drug and a national essential drug list (2018 edition) drug. Fei Tong ® is currently the only domestic caffeine citrate injection that has passed the drug consistency evaluation, the drug in order to ensure the same clinical efficacy as the original product, product quality standards are higher, pharmacoeconomic value is better, by China Resources Shuanghe wholly-owned subsidiary Shuanghe Limin R & D and production, after 6 years of research and development and 3 years of registration and approval, during which a number of top pediatric experts to participate in the guidance and strong support.
Feng Yi, chairman of CR Shuanghe, said that CR Shuanghe regards pediatrics as an important strategic development area and is committed to the research and development of pediatric drugs. As the only self-developed lung surfactant in China, the company's original product Keliso has brought the dawn of life to nearly 300,000 newborns in more than ten years on the market; pediatric compound amino acids lead the market with academics and benefit more children with nutritional concepts. In order to promote the improvement of neonatal medical level, the company has long been actively cooperating with the Chinese Medical Doctor Association, the Chinese Medical Association and other industry associations to carry out projects to promote the development of China's neonatal cause. ACTIVITIES SUCH AS NICU'S WESTWARD JOURNEY, HAND-IN-HAND ACTION, RAINBOW PROJECT, AND KELISU RESEARCH FUND HAVE PROMOTED THE BALANCED DEVELOPMENT OF CHINA'S MEDICAL RESOURCES AND PRACTICED THE SOCIAL RESPONSIBILITY OF CR SHUANGHE. The company will be committed to promoting the listing of more children's drugs, assume the responsibility of children's safe drug use, and actively carry out various academic activities, provide academic platforms, and contribute more to the development of China's neonatal medicine.
China Resources Shuanghe said that the successful listing of Fei Tong ® in the country will provide more clinical choices, benefit more children, and play a positive role in promoting the vigorous development of China's neonatal medical cause.
This article originated from Easy Publishing
![17 billion! Crus's family is amazing: Shuanghe, Sanjiu, Jiangzhong, Dong'a...[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)